2023 World Conference on Lung Cancer (Posters)-P2.09. Amivantamab vs Real World Therapies for Advanced NSCLC with EGFR Exon20ins in China

Pdf Summary

This study compares the clinical benefits of the targeted therapy drug amivantamab with real-world therapies in patients with advanced non-small cell lung cancer (NSCLC) who have a specific genetic mutation (EGFR Exon20ins). The study evaluates data from the CHRYSALIS study (which looked at the effectiveness of amivantamab) and a real-world external cohort (EC) in China.<br /><br />The CHRYSALIS study found that patients with NSCLC and EGFR Exon20ins mutations had durable responses to amivantamab. However, since the study was non-randomized, this research aims to compare the outcomes of amivantamab treatment in CHRYSALIS with systemic anti-cancer therapy (SACT) in the EC.<br /><br />To conduct the comparison, patients from the CHRYSALIS study who met eligibility criteria and received the recommended dose of amivantamab were included. A similar cohort was selected from a lung cancer multi-center electronic medical records (EMR) database and a hospital. The EC patients had previously received platinum-based chemotherapy and at least one SACT after their Exon20ins diagnosis.<br /><br />The analysis included 115 CHRYSALIS patients and 41 EC patients. The results showed that the median progression-free survival (PFS) was numerically better in the CHRYSALIS group, but not significantly different from the EC group. However, the time to next therapy (TTNT) was significantly longer in the CHRYSALIS group. The overall survival (OS) was not significantly different between the two groups. The CHRYSALIS group also had a higher overall response rate (ORR) compared to the EC group.<br /><br />In conclusion, this study demonstrates the clinical benefits of amivantamab in the real-world setting in China. The results show that patients with NSCLC and EGFR Exon20ins mutations who received amivantamab had significantly longer TTNT and higher ORR than those who received current real-world therapies. These findings suggest that amivantamab should be considered as a standard of care for this specific population.

Asset Subtitle

Shun Lu

Meta Tag

Speaker Shun Lu

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

amivantamab

non-small cell lung cancer

EGFR Exon20ins

CHRYSALIS study

real-world therapies

systemic anti-cancer therapy

progression-free survival

time to next therapy

overall response rate

standard of care